LUKE MIELS
Board of Directors member
Luke joined GSK as President, Global Pharmaceuticals in September 2017. He is a member of the GSK Corporate Executive Team and a Board Member for ViiV Healthcare.
At GSK, he is responsible for commercialising a portfolio of medicines and vaccines with annual sales of more than £20 billion and operations in over 100 markets.
His previous role was Executive Vice President of AstraZeneca’s European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.
Luke joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division. Before then, he held roles of increasing seniority at Sanofi-Aventis in Asia and the US. He also co-led the US integration of Sanofi and Aventis. Prior to that, he held general management roles in Thailand and New Zealand, following his entry into the industry in Australia.
He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.
YOU MAY ALSO BE INTERESTED IN
Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.
Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.
NP-GBL-HVX-COCO-220025 November 2024
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
